Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q3 2025 value amounting to $304.3 million.

  • Agios Pharmaceuticals' Long-Term Investments fell 5359.87% to $304.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $304.3 million, marking a year-over-year decrease of 5359.87%. This contributed to the annual value of $638.3 million for FY2024, which is 206857.82% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Long-Term Investments stood at $304.3 million for Q3 2025, which was down 5359.87% from $400.5 million recorded in Q2 2025.
  • Agios Pharmaceuticals' Long-Term Investments' 5-year high stood at $655.9 million during Q3 2024, with a 5-year trough of $21.6 million in Q1 2021.
  • Over the past 5 years, Agios Pharmaceuticals' median Long-Term Investments value was $266.4 million (recorded in 2021), while the average stood at $269.5 million.
  • Per our database at Business Quant, Agios Pharmaceuticals' Long-Term Investments crashed by 9062.2% in 2023 and then skyrocketed by 206857.82% in 2024.
  • Agios Pharmaceuticals' Long-Term Investments (Quarter) stood at $266.4 million in 2021, then increased by 17.83% to $313.9 million in 2022, then plummeted by 90.62% to $29.4 million in 2023, then soared by 2068.58% to $638.3 million in 2024, then crashed by 52.32% to $304.3 million in 2025.
  • Its Long-Term Investments stands at $304.3 million for Q3 2025, versus $400.5 million for Q2 2025 and $531.3 million for Q1 2025.